|
1
|
Hirschi B, Gallmeier E, Ziesch A,
Marschall M and Kolligs FT: Genetic targeting of B-RafV600E affects
survival and proliferation and identifies selective agents against
BRAF-mutant colorectal cancer cells. Mol Cancer. 13:1222014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:686–691. 2017.
View Article : Google Scholar
|
|
3
|
Tan S, Peng X, Peng W, Zhao Y and Wei Y:
Enhancement of oxaliplatin-induced cell apoptosis and tumor
suppression by 3-methyladenine in colon cancer. Oncol Lett.
9:2056–2062. 2015.PubMed/NCBI
|
|
4
|
Fan F, Gray MJ, Dallas NA, Yang AD, Van
Buren G II, Camp ER and Ellis LM: Effect of chemotherapeutic stress
on induction of vascular endothelial growth factor family members
and receptors in human colorectal cancer cells. Mol Cancer Ther.
7:3064–3070. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Luo C, Yuan D, Li X, Yao W, Luo G, Chi X,
Li H, Irwin MG, Xia Z and Hei Z: Propofol attenuated acute kidney
injury after orthotopic liver transplantation via inhibiting gap
junction composed of connexin 32. Anesthesiology. 122:72–86. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen X, Kong X, Zhuang W, Teng B, Yu X,
Hua S, Wang S, Liang F, Ma D, Zhang S, et al: Dynamic changes in
protein interaction between AKAP95 and Cx43 during cell cycle
progression of A549 cells. Sci Rep. 6:212242016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sirnes S, Bruun J, Kolberg M, Kjenseth A,
Lind GE, Svindland A, Brech A, Nesbakken A, Lothe RA, Leithe E and
Rivedal E: Connexin43 acts as a colorectal cancer tumor suppressor
and predicts disease outcome. Int J Cancer. 131:570–581. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gielen PR, Aftab Q, Ma N, Chen VC, Hong X,
Lozinsky S, Naus CC and Sin WC: Connexin43 confers Temozolomide
resistance in human glioma cells by modulating the mitochondrial
apoptosis pathway. Neuropharmacology. 75:539–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu M, Zhang C, Li L, Dong S, Zhang N and
Tong X: Cx43 reverses the resistance of A549 lung adenocarcinoma
cells to cisplatin by inhibiting EMT. Oncol Rep. 31:2751–2758.
2014.PubMed/NCBI
|
|
10
|
Lin S, Lei K, Du W, Yang L, Shi H, Gao Y,
Yin P, Liang X and Liu J: Enhancement of oxaliplatin sensitivity in
human colorectal cancer by hypericin mediated photodynamic therapy
via ROS-related mechanism. Int J Biochem Cell Biol. 71:24–34. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang Q, You T, Yuan D, Han X, Hong X, He
B, Wang L, Tong X, Tao L and Harris AL: Cisplatin and oxaliplatin
inhibit gap junctional communication by direct action and by
reduction of connexin expression, thereby counteracting cytotoxic
efficacy. J Pharmacol Exp Ther. 333:903–911. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yuan D, Wang Q, Wu D, Yu M, Zhang S, Li L,
Tao L and Harris AL: Monocyte-endothelial adhesion is modulated by
Cx43-stimulated ATP release from monocytes. Biochem Biophys Res
Commun. 420:536–541. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luo C, Yuan D, Zhao W, Chen H, Luo G, Su G
and Hei Z: Sevoflurane ameliorates intestinal
ischemia-reperfusion-induced lung injury by inhibiting the
synergistic action between mast cell activation and oxidative
stress. Mol Med Rep. 12:1082–1090. 2015.PubMed/NCBI
|
|
14
|
Lee W, Belkhiri A, Lockhart AC, Merchant
N, Glaeser H, Harris EI, Washington MK, Brunt EM, Zaika A, Kim RB
and El-Rifai W: Overexpression of OATP1B3 confers apoptotic
resistance in colon cancer. Cancer Res. 68:10315–10323. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Leone F, Artale S, Marino D, Cagnazzo C,
Cascinu S, Pinto C, Fornarini G, Tampellini M, Di Fabio F,
Sartore-Bianchi A, et al: Panitumumab in combination with
infusional oxaliplatin and oral capecitabine for conversion therapy
in patients with colon cancer and advanced liver metastases. The
MetaPan study. Cancer. 119:3429–3435. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Taieb J, Zaanan A, Le Malicot K, Julié C,
Blons H, Mineur L, Bennouna J, Tabernero J, Mini E, Folprecht G, et
al: Prognostic effect of BRAF and KRAS mutations in patients with
stage III colon cancer treated with leucovorin, fluorouracil, and
oxaliplatin with or without cetuximab: A post hoc analysis of the
PETACC-8 trial. JAMA Oncol. 1–11. 2016.PubMed/NCBI
|
|
17
|
Anderson BJ and Peterson LL: Systemic
capillary leak syndrome in a patient receiving adjuvant oxaliplatin
for locally advanced colon cancer. J Oncol Pharm Pract. 22:725–728.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Segretain D, Decrouy X, Dompierre J,
Escalier D, Rahman N, Fiorini C, Mograbi B, Siffroi JP, Huhtaniemi
I, Fenichel P and Pointis G: Sequestration of connexin43 in the
early endosomes: An early event of Leydig cell tumor progression.
Mol Carcinog. 38:179–187. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Leithe E, Sirnes S, Omori Y and Rivedal E:
Downregulation of gap junctions in cancer cells. Crit Rev Oncog.
12:225–256. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mesnil M, Crespin S, Avanzo JL and
Zaidan-Dagli ML: Defective gap junctional intercellular
communication in the carcinogenic process. Biochim Biophys Acta.
1719:125–145. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kardami E, Dang X, Iacobas DA, Nickel BE,
Jeyaraman M, Srisakuldee W, Makazan J, Tanguy S and Spray DC: The
role of connexins in controlling cell growth and gene expression.
Prog Biophys Mol Biol. 94:245–264. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shao Q, Wang H, McLachlan E, Veitch GI and
Laird DW: Down-regulation of Cx43 by retroviral delivery of small
interfering RNA promotes an aggressive breast cancer cell
phenotype. Cancer Res. 65:2705–2711. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Avanzo JL, Mesnil M, Hernandez-Blazquez
FJ, Mackowiak II, Mori CM, da Silva TC, Oloris SC, Gárate AP,
Massironi SM, Yamasaki H and Dagli ML: Increased susceptibility to
urethane-induced lung tumors in mice with decreased expression of
connexin43. Carcinogenesis. 25:1973–1982. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He B, Tong X, Wang L, Wang Q, Ye H, Liu B,
Hong X, Tao L and Harris AL: Tramadol and flurbiprofen depress the
cytotoxicity of cisplatin via their effects on gap junctions. Clin
Cancer Res. 15:5803–5810. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hong X, Wang Q, Yang Y, Zheng S, Tong X,
Zhang S, Tao L and Harris AL: Gap junctions propagate opposite
effects in normal and tumor testicular cells in response to
cisplatin. Cancer Lett. 317:165–171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao Y, Liu B, Wang Q, Yuan D, Yang Y,
Hong X, Wang X and Tao L: Propofol depresses the cytotoxicity of
X-ray irradiation through inhibition of gap junctions. Anesth
Analg. 112:1088–1095. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sanson M, Marcaud V, Robin E, Valéry C,
Sturtz F and Zalc B: Connexin 43-mediated bystander effect in two
rat glioma cell models. Cancer Gene Ther. 9:149–155. 2002.
View Article : Google Scholar : PubMed/NCBI
|
